---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-064145"
form_type: "8-K"
ticker: "SVRA"
cik: "0001160308"
company_name: "Savara Inc"
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:45:18.838570+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close

## Summary
- $30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
- Interest-only period of 36 months (extendable to 60 months upon FDA approval); floating rate of prime+1.45% (floor 6%+1.45%).
- No warrants issued; loan matures April 1, 2030; collateral includes tangible assets (negative pledge on IP).
- Milestone triggers: $80M available upon FDA approval (by end of 2025 if priority review), $20M upon revenue milestone post-2027, $70M at Hercules discretion.

## SEC filing metadata
- accession: 0001193125-25-064145
- form_type: 8-K
- ticker: SVRA
- cik: 0001160308
- company_name: Savara Inc
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1160308/000119312525064145/0001193125-25-064145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1160308/000119312525064145/d936539d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-064145
- JSON: https://secwatch.observer/filing/0001193125-25-064145.json
- Plain text: https://secwatch.observer/filing/0001193125-25-064145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.